chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient stated nausea shortly after vaccines administer, fever later that evening 10/13/17 eyelids red/irritated.
This spontaneous report as received from a pharmacist refers to a newborn male patient of unknown age. On 08-NOV-2012 03:46, the patient was vaccinated with RECOMBIVAX HB that had been exposed to temperatures below 32F for 6 hours. During that 6 hour time period, the vaccine was exposed to 28.8F for 1.5 hours. Administration route was not reported. Two lot# were involved and the lot# were reported as: 0294AE, expiry date on 06-SEP-2014; and 0385AE, expiry date on 08-NOV-2014. It was unspecified which lot# the patient was administered. The outcome of event was unknown. It was unspecified if the patient sought medical attention. This is one of several reports received from the same source. Additional information has been requested.
I began having a Crohn's disease flare.  The symptoms are lessening now , but I was required to increase my mesalamine dosage to curb the symptoms.
administered 0.3 mls of undiluted monovalent pediatric pfizer vaccine to adult patient. calculated dose to be between 30 and 40 mcg (dependent on amount of overflow initially in vial). pt did not experience any negative effects or adverse effects from the vaccine. notified pcp of incident
headache, sore throat, fever, cough, pressure in the chest (due to coughing), chills.
Doses administered past the published expiry; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Doses administered past the published expiry) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Doses administered past the published expiry). On 11-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Doses administered past the published expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   No concomitants were reported No treatments were reported
pt recvd pneumococcal vax in NOV91 & devel a large local reaction @ inject site w/induration & local cellulitis; there was no systemic reaction;
On 11/14/11 office visit (fever 103.6) cannot weight bear, painful (L) knee. Shaky/weak with fever. (L) thigh vaccine site pink VARIVAX to (L) thigh S/Q on 11/10/11 mod. blisters to injection site & buttock. 11/16/11 still walking, stiff.
Started w/ nauseau and diarhea, shaking and chills (even in hot climate), take ibuprofen and peptobismalevery three hours, dreams, weird fever dreams, left leg burning, lower teeth pain, joint pain in left hand (unusual). After two weeks burning dissapeared, everything else lasted only 4 days
Erythema, induration redness with small blisters around site. 10cm induration and 4cm area of more intense erythema with multiple vesicles notes.
arm was sore for several; tired for the rest of the day; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm was sore for several) and FATIGUE (tired for the rest of the day) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031L20A and 030A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-Feb-2021, the patient experienced PAIN IN EXTREMITY (arm was sore for several) and FATIGUE (tired for the rest of the day). At the time of the report, PAIN IN EXTREMITY (arm was sore for several) and FATIGUE (tired for the rest of the day) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Action taken with mRNA-1273 in response to the drug was no change. No concomitant medication information was provided. No treatment medication information was provided.    This case was linked to MOD-2021-064419 (Patient Link).
did not sleep all night; lot of chills; Pain in arm; swollen; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (lot of chills), VACCINATION SITE PAIN (Pain in arm), VACCINATION SITE SWELLING (swollen) and INSOMNIA (did not sleep all night) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Feb-2021, the patient experienced CHILLS (lot of chills), VACCINATION SITE PAIN (Pain in arm) and VACCINATION SITE SWELLING (swollen). On an unknown date, the patient experienced INSOMNIA (did not sleep all night). At the time of the report, CHILLS (lot of chills), VACCINATION SITE PAIN (Pain in arm), VACCINATION SITE SWELLING (swollen) and INSOMNIA (did not sleep all night) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication reported  No treatment information was provided
body aches; a low grade fever; chills; fatigue; was falling asleep; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). Other Case identifier(s): 2023NVX-US-000000150 (Novavax).  A 61-year-old female patient received BNT162b2 (BNT162B2), on 08Apr2021 as dose 2, single (Batch/Lot number: unknown) at the age of 61 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: BNT162b2 (Dose 1, single), administration date: 19Mar2021, when the patient was 61-year-old, for COVID-19 immunization, reaction(s): "Feverish", "she had a severe headache", "nausea", "body aches", "chills", "did not eat for 2 days". The following information was reported: PYREXIA (non-serious) with onset 08Apr2021, outcome "unknown", described as "a low grade fever"; PAIN (non-serious) with onset 08Apr2021, outcome "unknown", described as "body aches"; CHILLS (non-serious) with onset 08Apr2021, outcome "unknown"; FATIGUE (non-serious) with onset 08Apr2021, outcome "unknown"; SOMNOLENCE (non-serious) with onset 08Apr2021, outcome "unknown", described as "was falling asleep". Relevant laboratory tests and procedures are available in the appropriate section.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
This spontaneous report was received from a consumer via Glaxosmithkline, referring to a 67-year-old patient at the reporting time of unknown gender. The patient's pertinent medical history, drug reactions/allergies and concomitant therapies were not provided. On an unknown date (at age of 62-year-old), the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (reported as older shingles shot) (strength, dose, dose number, route, lot# and expiration date were not provided) for prophylaxis. On an unknown date (at age around 65-year-old), the patient was vaccinated with varicella zoster vaccine rge (cho) (SHINGRIX) (reported as newer shot) but only 1 injection (strength, dose, route, indication, lot# and expiration date were not provided). On an unknown date, the patient had shingles (herpes zoster). The outcome of event and the causality assessment were not provided.
After getting the vaccine, the phlegm problem he'd had for years went away; This case was reported by a consumer via call center representative and described the occurrence of unexpected therapeutic effect in a 89-year-old male patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis.   The patient's past medical history included phlegm (had a chronic condition for many years).   On 17th April 2022, the patient received the 1st dose of Menveo (intramuscular) .5 ml. In April 2022, several days after receiving Menveo, the patient experienced unexpected therapeutic effect. On an unknown date, the outcome of the unexpected therapeutic effect was unknown.   It was unknown if the reporter considered the unexpected therapeutic effect to be related to Menveo.     Additional Information: GSK Receipt Date: 13-MAY-2022 Reporters comment: The patient self-reported the case. The patient had a chronic condition for many years where phlegm comes into his mouth several times a day.   The patient received Menveo in left arm. He reported that, a few days after getting the Menveo vaccine, the phlegm problem he had for years went away. The reporter did not consent to follow-up.
Pain in arm when lifted at a right angle and above her head; This is a spontaneous report from a non-contactable consumer (patient). A 44-year-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number and Expiry date: Unknown), via an unspecified route of administration on an unknown date in Jan2021 as single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient historical vaccine included Tetanus shot hurt more and had pain. On 27Jan2021, the patient experienced pain in arm and described it as there was no pain when arm was down, but she did experience pain when she lifted her arm at a right angle and above her head. The patient stated that Tetanus shot hurted more compared to this pain. She stated that the pain reached its peak about 12 hours ago and subsided at the time of report. At the time of report, the patient did not receive second dose of COVID-19 Vaccine. The outcome of the event was reported as recovering.  No follow up attempts are possible. Information about lot/batch number cannot not be obtained.
Patient Developed swelling and urticaria approximately 15 minutes post injection.  Recevied Epinephrine, Solu-medrol and Albuterol Benadryl.
Second dose not received in allowed time window; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose not received in allowed time window) in an 18-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose not received in allowed time window). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose not received in allowed time window) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
My RA began to really act up.  My whole body stiffened up-(legs, hands, hips, back).  Lower back made it hart to bend over, Rt shoulder had a swelling and hurt at a pinch point in shoulder, my rt hip hurt when I walked more than 0.25 miles, my hands swelled and could not use hand well. Did not initially link to Covid shot, so called my Rheumatologist on the sixth day that the symptoms continued.  Received prescription to reduce muscle  tension and an anti inflamatory.  However, a couple of days after talking to my doctor and before taking any of the prescribed meds, the symptoms went away and since that time, my RA is back to typical old symptoms and pain level.
Information has been received from a physician via a company representative referring to 5 patients of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On unknown dates the patients were vaccinated with second doses of PNEUMOVAX 23 (dose, route, lot# and expiration date were not reported). Concomitant drug was not reported. On unknown dates the 5 patients all experienced local injection site reaction. It was unknown whether the patients sought medical attention. The outcome of the causality were unknown. Additional information has been requested.
PATIENT RECEIVED MODERNA VACCINE AS A MINOR INSTEAD OF PFIZER BY ACCIDENT.
periorbital erythema, hives on face-no involvement w/other areas, none @ inj site, DPH elixir given PO in office;
slight nosebleeds; chills for few days; This spontaneous case was reported by a consumer and describes the occurrence of EPISTAXIS (slight nosebleeds) and CHILLS (chills for few days) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016M20A and 016M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 16-Feb-2021, the patient experienced EPISTAXIS (slight nosebleeds) and CHILLS (chills for few days). At the time of the report, EPISTAXIS (slight nosebleeds) and CHILLS (chills for few days) outcome was unknown.            No Concomitant Medications were  provided by Reporter. No Treatment Medications were  provided by Reporter.   This case was linked to MOD-2021-022042 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 22-Feb-2021: confirm information is NNI
DIZZY; FOG HEADDED; CHILLS; TIRED; MUSCLE PAIN IN NECK; LOW GRADE FEVER; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The company is unable to perform follow up to request batch/lot numbers. No concomitant medications were reported.  On an unspecified date, the subject experienced dizzy, fog headded, chills, tired, muscle pain in neck, and low grade fever. Treatment medications (dates unspecified) included: acetylsalicylic acid, and paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from tired, muscle pain in neck, low grade fever, chills, dizzy, and fog headded. This report was non-serious.
Initially approximately 5 minutes following injection hot flashes occured, continued intermittently, around 1:30pm Tingling started in right jaw in close proximity to ear, spread to approximately half way across right cheek from below eye to lower jaw, tingling sensation to base of right side of tongue that felt similar to that when you get a novicane injection, progressed to numbness to same area, tingling started to subside a few hours following, however, when touching/ applying light pressure to that area of face and progressing toward R side of top and bottom lip the feeling of pins and needles occurs, pressure sensation is felt to the right side of the face, with new addition of numbness/tingling to right side of top and bottom lip.
off label use; Booste; covid-19 treatment; covid-19 treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 69-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 28Jan2021 as dose 1, single (Batch/Lot number: unknown), in right arm, on 20Feb2021 as dose 2, single (Batch/Lot number: unknown), in right arm, on 27Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm and on 20Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 69 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Type 2 diabetes" (unspecified if ongoing); "Hypertension" (unspecified if ongoing); "Glaucoma" (unspecified if ongoing). Concomitant medication(s) included: LIPITOR, start date: Mar2000, stop date: 11May2022; ANASTROZOLE, start date: Aug2017.  The following information was reported: OFF LABEL USE (medically significant), outcome "unknown"; IMMUNISATION (medically significant), outcome "unknown", described as "Booste"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "covid-19 treatment". Therapeutic measures were taken as a result of off label use, immunisation, vaccination failure, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Information has been received from a Registered Nurse (R.N.) concerning a female patient in her 70's with hypertension, penicillin allergy and problem with nerves (undefined) who on 31-MAY-2007 was vaccinated with a second dose of Pneumovax 23, lot 655499/0988F. The patient got the first Pneumovax 23 7-10 years ago. On 31-MAY-2007 the nurse reported that the patient developed cellulitis from her shoulder to elbow after getting the second Pneumovax 23 vaccine. The vaccination arm began to ache after the vaccination and by the next day was swollen, hot and tender. The treatment was diphenhydramine hydrochloride (BENADRYL), levofloxacin (LEVAQUIN) and betamethasone valerate (VALISONE CREAM). The patient was not recovered as of this report date. The reporter felt that the treatment with diphenhydramine hydrochloride (BENADRYL), levofloxacin (LEVAQUIN) and betamethasone valerate (VALISONE CREAM) was to prevent patient from being serious and considered this as a serious other medical event. Additional information has been requested.
arm soreness up until last night really bad pain; arm so sore extremely tender to the touch; pain; threw up from 11-12; nausea and fever of 100F to 102F; nausea and fever of 100F to 102F; chills; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm soreness up until last night really bad pain), TENDERNESS (arm so sore extremely tender to the touch), PAIN (pain), VOMITING (threw up from 11-12) and NAUSEA (nausea and fever of 100F to 102F) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was not reported by the reporter.  Concomitant products included SERTRALINE HYDROCHLORIDE (ZOLOFT) for an unknown indication.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (arm soreness up until last night really bad pain), TENDERNESS (arm so sore extremely tender to the touch), PAIN (pain), VOMITING (threw up from 11-12), NAUSEA (nausea and fever of 100F to 102F), PYREXIA (nausea and fever of 100F to 102F) and CHILLS (chills). The patient was treated with PARACETAMOL (TYLENOL) ongoing since an unknown date at an unspecified dose and frequency; ONDANSETRON (ZOFRAN [ONDANSETRON]) ongoing since an unknown date at an unspecified dose and frequency and SUMATRIPTAN (IMITREX [SUMATRIPTAN]) ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (arm soreness up until last night really bad pain), TENDERNESS (arm so sore extremely tender to the touch), PAIN (pain), VOMITING (threw up from 11-12), NAUSEA (nausea and fever of 100F to 102F), PYREXIA (nausea and fever of 100F to 102F) and CHILLS (chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Information has been received from a nurse concerning an "18 to 19 year old" female consumer who on unspecified date in April 2008, was vaccinated with a "second dose" of GARDASIL (lot # not reported). There was no concomitant medication. The nurse reported that the patient "fainted ten minutes after vaccination." The nurse noted that "the patients who read the GARDASIL fact sheet prior to vaccination seemed more prone to fainting". It was reported that "most of the patients did not have breakfast and this may play a role because the vaccinations were given early in the day". The patient sought unspecified medical attention during an office visit. The patient recovered from fainting "on the same day". This is one of several reports from the same source. Additional information has been requested.
Terrible hair loss / Almost bald; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA (Terrible hair loss / Almost bald) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ALOPECIA (Terrible hair loss / Almost bald). At the time of the report, ALOPECIA (Terrible hair loss / Almost bald) outcome was unknown.            No concomitant medication was reported . no treatment medication was reported
Injection was giving in the left arm and as of July 8th  arm is still hurting where the shot was giving. Also pain is petruding in the back of rm and neck
Cold and shivering, low grade intermittent fever, intermittent ear pain, intermittent tingling tongue sensation. Blood coming out of one nostril (Felt like a brain bleed, which the patient has experienced in the past) and the inside of that nostril is "fire engine" red. Has experienced horrible balance after the vaccine. The back of her throat contains bright red and yellow patches. Her tongue has been dry and contains bumps. She states that she lost tone on the inside of the cheeks. She's had 2 breakouts of warts on the back of the tongue, looks like swollen taste buds and they are yellowish-white in color.
Extreme belly pain, difficulty eating, it?s been 23 days of diarrhea at this point and it has not yet stopped.
I was on the 2nd to last day of my period (March 16) when I got vaccinated. 16 days later (April 1st), I was having PMS symptoms, which is much sooner than usual. They included acne, mood swings, and cramping.  On April 6th, I began seeing some very light bleeding on my underwear. It was so light that I was hesitant to call it a period but too heavy to be considered spotting. I continued the light bleeding for 6 days, which is 2 days longer than my usual periods. My average cycle is 29 days long, but after the first dose of the moderna vaccine, it was only 23 days long. I have never had a cycle that short since I started tracking my cycles in 2017 and I have never had a period 6 days long with unusually light bleeding the entire time. I am aware that stress and other changes can cause unusual periods but I knew for a fact that I had been free of stress and very happy during this time frame and had no underlying issues as a healthy 22-year-old adult. It wasn't until I received my second dose of the vaccine that I made a connection between the unusual period and the vaccine. My cycles have become regular again, even after receiving the second dose.
I got COVID. Used home test to recognize (2/19/2023), confirmed on visit to local emergency care clinic (2/20/2023) where I was prescribed Paxlovid. Started taking Paxlovid 2/20/2023, as per instructions, was feeling better the next day and pretty much recovered by 2/24/2023.  Only remaining issue was a feeling that there was lots of mucus in my head that needed to come out. Came out over the next few weeks.